Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

IS FINALS AND REMOVALS > Transplantation Immunology > Flashcards

Transplantation Immunology Flashcards

1
Q

One of the MOST POLYMORPHIC
gene system known

A

Human
Leukocyte
Antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

in human leukocyte antigen, Associated protein is coded in the
______ in the
major histocompatibility complex

A

short arm of chromosome 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Can occur in special case in which
immunocompetent tissue is
transplanted into an
immunocompromised host (Bone
Marrow, Thymus, Fresh Whole Blood)

A

Graft vs
Host
Disease (GvHD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

T cells from the transplant recognize
the host MHC molecules as non
-self
and attack the host

A

gvhd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Preformed antibodies and complement
that reacts with donor

A

Hyperacute
“White graft”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Reactivation of sensitized T cells
Pre-sensitized T cells; due to low level of
antibody present in the body in
pretransplant period

A

Accelerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Primary activation of T cells
Development of allogenic reaction to
donor Ag

A

Acute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Causes are unclear , antibodies, immune
complex, slow cellular reaction, recurrence
of disease; side effects of
immunosuppressive drugs

A

Chronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HLA Typing in
Laboratory

A
  • DNA sequencing (Polymerase Chain
    Reaction)
  • Serological assay
  • Mixed lymphocyte culture / Mixed
    lymphocyte reaction (MLC/MLR)
  • Crossmatching
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

– Amplification and specific probes to
detect different alleles
– Highly specific / sensitive
– Method of choice

A

DNA SEQUENCING (POLYMERASE CHAIN
REACTION)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

– Cells from the donor and recipient are
reacted with a battery of antibodies,
each one of which is specific for a
different class I and II protein
– Complement is then added, and any
cell bearing an MHC protein
homologous to the known antibody
will lyse
– Satisfactory in most cases

A

SEROLOGICAL ASSAY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

“Stimulator” lymphocytes from a potential donor are first killed
by radiation and then mixed with live “responder” lymphocyte
from the recipient

A
  • MLC/MLR

Result: the greater the amount of DNA synthesis in the
responder cells, the more foreign are the Class I and II MHC
proteins of the donor cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

– The fetus is an allograft that is not rejected
– Trophoblast layer of the placenta does not allow maternal T cells
to enter the fetus

A

CROSSMATCHING

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

KINDS OF IMMUNOSUPRESSIVE AGENTS

A

*Corticosteroids
*Antimetabolic Agents
*Calcineurin Inhibitors
*Monoclonal antibodies
*Polyclonal antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

To suppress antigraft immune response in solid-organ and stem cell
transplantation

Increase susceptibility to infection, malignancies , and other
associated toxic side effects

A

IMMUNOSUPPRESSIVE AGENTS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

can cause uninhibited cell division if their
expression is altered or if they are mutated
into oncogenes

A
  • PROTO-ONCOGENES
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q
  • TUMOUR SUPPRESSOR GENES
A
  • PROTO-ONCOGENES
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

are characterized by slow growth restricted
anatomic location and do not cause deatH

A

BENIGN NEOPLASM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

MALIGNANT NEOPLASM OF

A

– is often referred as cancer or tumor.

They are
characterized by:
a. Anaplasia in which cells lose their differentiating features

b. Invasion of the body

c. Metastatic spread which can result in death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Often named by adding the suffix –oma (lipoma) to the cell
type but there are exceptions such as lymphomas,
melanomas, hepatoma

A

BENIGN TUMOR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Benign tumors arising from glands are called _____ and
those from epithelial surfaces are termed ________

A

Benign tumors arising from glands are called adenomas and
those from epithelial surfaces are termed polyps or
papillomas

22
Q

CHARACTERISTICS OF BENIGN TUMOR

A

Usually are encapsulated
Grow slowly
Usually are nonspreading
Have minimal mitotic activity
Resemble the parent tissue

23
Q

MALGNANT TUMOR those arising
from glandular epithelium are
called

A

adenocarcinoma

24
Q

Referred to as carcinoma or
cance

A

MALIGNANT
TUMOR

25
Q

CHARACTERISTIC
OF MALIGNANT
TUMOR

A

Increase in the number of cells that accumulate

Involves invasion of tissue

Dissemination by lymphatic spread or by seeding within a body cavity

Metastasis

Characteristic nuclear cellular features

Receptors for intergrin molecules

26
Q

is when the malignant cells travel through
the body, causing new foci of malignancy
until body function is so disrupted that death
occurs

A

METASTASIS

27
Q

Most widely used cancer staging
system

A

TNM
System

The T refers to the size and extent of the
main tumor. The main tumor is usually called
the primary tumor.
* The N refers to the the number of nearby
lymph nodes that have cancer.
* The M refers to whether the cancer has
metastasized. This means that the cancer has
spread from the primary tumor to other parts
of the body.

28
Q

Primary Tumor (T)

A

Primary Tumor (T)
* TX: Main tumor cannot be measured.

  • T0: Main tumor cannot be found.
  • T1, T2, T3, T4: Refers to the size and/or extent of the main
    tumor. The higher the number after the T, the larger the
    tumor or the more it has grown into nearby tissues. T’s may
    be further divided to provide more detail, such as T3a and
    T3b
29
Q

Regional Lymph Nodes (N)

A
  • NX: Cancer in nearby lymph nodes cannot be measured.
  • N0: There is no cancer in nearby lymph nodes.
  • N1, N2, N3: Refers to the number and location of lymph nodes that contain cancer. The higher the number after the N, the more lymph nodes that contain cancer.
30
Q

Distant Metastasis (M)

A
  • MX: Metastasis cannot be measured.
  • M0: Cancer has not spread to other parts of the body.
  • M1: Cancer has spread to other parts of the body.
31
Q

n the course of malignant
transformation of a cell, new
antigens or tumor associated
antigens develop at the cell
surface and the host recognize
malignant cells as “non self”

A

Tumor
Associated
Antigens
(TAA)

The quantity of TAA increases
proportionally with tumor growth
and decreases with effective
threrapeutic response

32
Q

TUMOR SASSOCIATED ANTIGEN- ABSAHIN ANG HABA POTA

A
33
Q

Oncofetal
Antigens

A

AFP AND CEA

34
Q

synthesized by fetal liver cells. Most
but not all hepatomas secrete
large amounts of AFP. Its presence
in serum is not diagnostic of
hepatoma but is merely suggestive

A

AFP OR ALPHA FETO PROTEIN

35
Q

– glycoprotein found in
glycocalyx of cells derived from
endoderm and present in gastro
intestinal carcinomas especially
cancer of colon

A

CARCINOEMBRYONIC ANTIGEN
(CEA)

36
Q

These viral “finger prints”
form a major part of the
evidence that links viruses
with human malignancy.

A

Virus –
Induced
TAA

37
Q

have
found in the cells of patients with
Burkitt’s Lymphoma and
Nasopharyngeal carcinom

A

EPSTEIN –BARR VIRUS (EBV)

38
Q

Virus –
Induced
TAA

AND WHERE THEY CNA BE FOUND

A
  • HEPATITIS B found in Primary Liver
    Cancer
  • HUMAN PAPILLOMA VIRUSES 16
    AND 18 in Cervical Cacinoma
  • HUMAN T-CELL LEUKEMIA VIRUS
    found in Adult T-Cell leukemia
39
Q

Antigens that can induce a protective immune response in the
host if they occur in the membrane of the malignant cell

A

Tumor Specific
Transplantation Antigens
(TSTA)

40
Q

Immunosurveillance READ

A
41
Q

EFFECTOR MECHANISM AGAINST CANCER

A
  • Monocyte / macrophage release lytic enzymes and
    phagocytose necrotic material
  • Antibody against tumour antigens
  • Induction of tumour-specific CTL and TIL
  • Initiation of NK / CTL cytotoxic responses
  • Release of cytokines / chemokines (TNFα, IFNs etc) and
    antiangiogenic factors
42
Q

Immunoediting- The Great Escape!

A

*Strong evidence that IR controls and
eradicates nascent cancer cells
*“Immunoediting” eventually produces low
antigenicity tumour cells
*Pressure from immune system coupled
with genomic instability selects for escape

43
Q

Three Es of Immunoediting

A

Elimination Equilibrium Escape

44
Q

– can detect expressed antigens using labeled antibodies,

A

Immunohistochemistry

45
Q

Many cancers are associated with particular karyotypes.
However, as more precise knowledge of the exact gene
defects present in various cancers is gained, testing for the
aberrant genes is becoming more prevalent.

A
  • Cytogenetic Studies
46
Q

Polymerase chain reaction (PCR) and its variants increase the inherent
level of DNA or RNA, allowing the detection of small populations of
cancer cells (including circulating cells in metastasis) and the detection
of mutations, deletions, and gene rearrangements/translocations

A

Nucleic Amplification Technique

47
Q

Nucleic acid probes capable of binding to sequences of interest are
tagged with fluorophors and applied to cells. Cells containing the
sequence of interest can be visualized with fluorescent microscopes.
Similar techniques using nonfluorescent labels such as enzymes and
silver stains are also becoming available

A

Flourescent In Situ Hybridization

48
Q

The goal of active immunotherapy is to have the patient
develop an immune response that will help eliminate the
tumor

A

ACTIVE IMMUNOTHERAPY

49
Q
  • Passive transfer of allogeneic cellular immunity from one
    person to another to fight cancer has many barriers:
  • Possible recipient rejection of foreign cells
  • Graft-versus-host disease (GVHD)
  • Fragility of live cells, although research models are being
    studied
A
  • PASSIVE IMMUNOTHERAPY
50
Q
A

IS FINALS AND REMOVALS (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions